Advances in molecular research have resulted in the emergence of promising treatments for advanced NSCLC, such as gefitinib, a targeted agent that effectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase (Yi et al., 2023). Here, EGFR is linked to non-small cell lung carcinoma.